1 min read

Market Context

Australia remains a highly attractive pharmaceutical market due to its strong regulatory framework and global credibility. However, registering medicinal products with the Therapeutic Goods Administration (TGA) requires more than just dossier submission.

In 2026, sponsors are facing increasing scrutiny around submission quality, GMP compliance, and lifecycle readiness—making strategic regulatory planning more important than ever.

Regulatory Explanation

To gain inclusion in the Australian Register of Therapeutic Goods (ARTG), sponsors must ensure:

  • Accurate CTD/eCTD submissions
  • Australia-specific Module 1 documentation
  • GMP clearance for manufacturing sites
  • Compliance with labeling and safety requirements

Even small gaps can lead to regulatory queries and approval delays.

Problem (Top 5 Pitfalls)

  1. Incomplete Module 1 Localization 
    Global dossiers often fail to address Australia-specific requirements, leading to avoidable deficiencies.
  2. GMP Clearance Delays 
    Missing or outdated GMP evidence remains one of the biggest causes of delayed approvals.
  3. Poor Submission Readiness 
    Submitting without a structured gap assessment increases the risk of multiple query cycles.
  4. Delayed Regulatory Query Responses 
    Slow or incomplete responses to TGA questions can significantly impact review timelines.
  5. Lack of Lifecycle Management Planning 
    Many sponsors focus only on approval, overlooking post-approval variations, renewals, and compliance updates.

Freyr Solution

Freyr supports sponsors with practical, end-to-end regulatory support in Australia, including:

  • Regulatory gap analysis and submission readiness assessment
  • TGA-compliant Module 1 preparation
  • Dossier compilation and eCTD publishing support
  • GMP clearance coordination
  • Regulatory query handling and lifecycle management (LCM) support

Outcome: Reduced delays, improved submission quality, and smoother regulatory pathways.

For global pharmaceutical companies, aligning international dossiers with Australia-specific expectations can be challenging.

Freyr helps bridge this gap by combining global regulatory expertise with local TGA understanding to support efficient and compliant market entry.

In Australia, successful medicine registration depends not only on scientific data—but also on regulatory execution.

Are your submissions prepared to avoid the most common approval pitfalls?

Connect with Freyr to strengthen your Australia registration strategy and reduce regulatory delays for medicinal products